The FDA Did The Right Thing By Approving a Novel Drug For A Disabling Disease

as seen in Forbes

The FDA’s decision reflects a thoughtful, not knee-jerk approach to its mission, which is to protect the public from fraudulent and unsafe substances. What’s at issue is how well eteplirsen works. And that it’s too expensive.